Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer.
作者： Javier Rodríguez , Ruth Zarate , Eva Bandres , Valentina Boni , Amaia Hernández
DOI: 10.1016/J.EJCA.2012.01.007
关键词:
摘要: … The DCR achieved in our cohort of mutated patients with the 131H/H genotype is higher … al. study 32 ), the use of ORR instead of DCR as a primary end-point and the inclusion of a more …
elsevier.com
sci-hub.se 参考文章(32)
Sébastien Dall’Ozzo, Sophie Tartas, Gilles Paintaud, Guillaume Cartron, Philippe Colombat, Pierre Bardos, Hervé Watier, Gilles Thibault, Rituximab-Dependent Cytotoxicity by Natural Killer Cells: Influence of FCGR3A Polymorphism on the Concentration-Effect Relationship Cancer Research. ,vol. 64, pp. 4664- 4669 ,(2004) , 10.1158/0008-5472.CAN-03-2862
Jan Pander, Hans Gelderblom, Ninja F. Antonini, Jolien Tol, Johan H.J.M. van Krieken, Tahar van der Straaten, Cornelis J.A. Punt, Henk-Jan Guchelaar, Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. European Journal of Cancer. ,vol. 46, pp. 1829- 1834 ,(2010) , 10.1016/J.EJCA.2010.03.017
Li-Xin Qiu, Chen Mao, Jian Zhang, Xiao-Dong Zhu, Ru-Yan Liao, Kai Xue, Jin Li, Qing Chen, Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies European Journal of Cancer. ,vol. 46, pp. 2781- 2787 ,(2010) , 10.1016/J.EJCA.2010.05.022
W.-Ludo van der Pol, Marc D. Jansen, Wim J. Sluiter, Bart van de Sluis, Fredriek G. J. Leppers-van de Straat, Tetsuo Kobayashi, Rudi G. J. Westendorp, Tom W. J. Huizinga, Jan G. J. van de Winkel, Evidence for non-random distribution of Fcγ receptor genotype combinations Immunogenetics. ,vol. 55, pp. 240- 246 ,(2003) , 10.1007/S00251-003-0574-9
François Ghiringhelli, Cedric Menard, Pierre Emmanuel Puig, Sylvain Ladoire, Stephan Roux, François Martin, Eric Solary, Axel Le Cesne, Laurence Zitvogel, Bruno Chauffert, Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients Cancer Immunology, Immunotherapy. ,vol. 56, pp. 641- 648 ,(2007) , 10.1007/S00262-006-0225-8
Pierpaolo Correale, Monica Marra, Cinzia Remondo, Cristina Migali, Gabriella Misso, Felice Paolo Arcuri, Maria Teresa Del Vecchio, Antonietta Carducci, Lucia Loiacono, Pierfrancesco Tassone, Alberto Abbruzzese, Pierosandro Tagliaferri, Michele Caraglia, Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC) European Journal of Cancer. ,vol. 46, pp. 1703- 1711 ,(2010) , 10.1016/J.EJCA.2010.03.005
Greta Garrido, Pablo Lorenzano, Belinda Sánchez, Irene Beausoleil, Daniel F. Alonso, Rolando Pérez, Luis E. Fernández, T cells are crucial for the anti-metastatic effect of anti-epidermal growth factor receptor antibodies Cancer Immunology, Immunotherapy. ,vol. 56, pp. 1701- 1710 ,(2007) , 10.1007/S00262-007-0313-4
John R. Desjarlais, Greg A. Lazar, Eugene A. Zhukovsky, Seung Y. Chu, Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discovery Today. ,vol. 12, pp. 898- 910 ,(2007) , 10.1016/J.DRUDIS.2007.08.009
Geraldine Perkins, Astrid Lièvre, Carole Ramacci, Tchao Méatchi, Aurélien de Reynies, Jean-François Emile, Valérie Boige, Gorana Tomasic, Jean-Baptiste Bachet, Fréderic Bibeau, Olivier Bouché, Frédérique Penault-Llorca, Jean-Louis Merlin, Pierre Laurent-Puig, Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer. International Journal of Cancer. ,vol. 127, pp. 1321- 1331 ,(2010) , 10.1002/IJC.25152
Raphaël Maréchal, Jef De Schutter, Nathalie Nagy, Pieter Demetter, Arnaud Lemmers, Jacques Devière, Isabelle Salmon, Sabine Tejpar, Jean-Luc Van Laethem, None, Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients. BMC Cancer. ,vol. 10, pp. 340- 340 ,(2010) , 10.1186/1471-2407-10-340